<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00052572</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000258542</org_study_id>
    <secondary_id>MSKCC-02046</secondary_id>
    <secondary_id>NCI-5342</secondary_id>
    <nct_id>NCT00052572</nct_id>
  </id_info>
  <brief_title>Ixabepilone in Treating Patients With Relapsed or Refractory Lymphoproliferative Disorders</brief_title>
  <official_title>A Multicenter Phase II Study Of BMS 247550 (Epothilone B Analogue) In Indolent Lymphoproliferative Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing&#xD;
      so they stop growing or die.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of ixabepilone in treating patients who&#xD;
      have relapsed or refractory lymphoproliferative disorders.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the frequency and duration of complete and partial response rates for patients&#xD;
           with relapsed or refractory indolent lymphoproliferative disorders treated with&#xD;
           ixabepilone.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the time to progression and overall survival of patients treated with this&#xD;
           drug.&#xD;
&#xD;
        -  Determine the toxicity of this drug in these patients.&#xD;
&#xD;
      OUTLINE: This is an open-label study.&#xD;
&#xD;
      Patients receive ixabepilone IV over 1 hour weekly for 3 weeks. Courses repeat every 4 weeks&#xD;
      in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 35 patients will be accrued for this study within 1-1.5 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2002</start_date>
  <completion_date type="Actual">July 2007</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean and median duration of response</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean and median duration of progression-free and overall survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Probability of polymerase chain reaction negativity after treatment</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ixabepilone</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed relapsed/recurrent or refractory indolent lymphoproliferative&#xD;
             disorder of 1 of the following types:&#xD;
&#xD;
               -  Chronic lymphocytic leukemia&#xD;
&#xD;
                    -  Absolute lymphocytosis greater than 5,000/mm^3&#xD;
&#xD;
                    -  B-cell phenotype (CD 19, 20, or 23 positive) with more than 30% bone marrow&#xD;
                       lymphocytes&#xD;
&#xD;
               -  B-cell small lymphocytic lymphoma&#xD;
&#xD;
               -  Marginal zone B-cell lymphoma&#xD;
&#xD;
               -  Grade I-III follicle center cell lymphoma&#xD;
&#xD;
               -  Waldenstrom's macroglobulinemia&#xD;
&#xD;
               -  Mantle cell lymphoma&#xD;
&#xD;
          -  At least 1 unidimensionally measurable lesion for patients with non-Hodgkin's lymphoma&#xD;
&#xD;
               -  At least 2 cm by conventional techniques&#xD;
&#xD;
          -  No active brain metastases&#xD;
&#xD;
               -  Treated CNS disease allowed&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Karnofsky 60-100%&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  At least 3 months&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,000/mm^3 (500/mm^3 if there is lymphomatous involvement&#xD;
             of the bone marrow)&#xD;
&#xD;
          -  Platelet count ≥ 50,000/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  AST or ALT ≤ 2.5 times ULN (4 times ULN if there is liver involvement)&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine ≤ 2 times ULN OR&#xD;
&#xD;
          -  Creatinine clearance ≥ 50 mL/min&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No history of orthostatic hypotension&#xD;
&#xD;
          -  No myocardial infarction, cerebrovascular accident, or transient ischemic attack&#xD;
             within the past 3 months&#xD;
&#xD;
          -  No New York Heart Association class III or IV congestive heart failure&#xD;
&#xD;
          -  No unstable angina pectoris&#xD;
&#xD;
          -  No cardiac arrhythmia&#xD;
&#xD;
          -  No uncontrolled hypertension requiring manipulation of antihypertensive medications&#xD;
&#xD;
          -  No evidence of any of the following by echocardiogram:&#xD;
&#xD;
               -  Acute ischemia&#xD;
&#xD;
               -  Significant conduction abnormality&#xD;
&#xD;
                    -  Bifascicular block&#xD;
&#xD;
                    -  2^nd- or 3^rd-degree atrioventricular block&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No other immunodeficiency&#xD;
&#xD;
          -  No known severe hypersensitivity reaction to agents containing Cremophor EL&#xD;
&#xD;
          -  No ongoing or active infection&#xD;
&#xD;
          -  Febrile episodes up to 38.5° Celsius allowed in the absence of infection&#xD;
&#xD;
          -  No other concurrent uncontrolled illness that would preclude study participation&#xD;
&#xD;
          -  No psychiatric illness or social situation that would preclude study compliance&#xD;
&#xD;
          -  No preexisting grade II or greater sensory neuropathy&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  At least 3 months since prior monoclonal antibodies (unless there is clearly&#xD;
             documented evidence of disease progression after therapy)&#xD;
&#xD;
          -  At least 3 months since prior radioimmunotherapy&#xD;
&#xD;
          -  No prior allogeneic bone marrow transplantation&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  At least 4 weeks since prior cytotoxic chemotherapy (6 weeks for mitomycin,&#xD;
             nitrosoureas, or carmustine) and recovered&#xD;
&#xD;
          -  No more than 4 prior chemotherapy regimens (including high-dose chemotherapy [HDC] for&#xD;
             patients with relapsed disease &gt; 100 days after completion of HDC)&#xD;
&#xD;
               -  Cytoreduction plus HDC is considered 1 chemotherapy regimen&#xD;
&#xD;
          -  No other concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  At least 7 days since prior steroids&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  More than 3 weeks since prior radiotherapy and recovered&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  More than 4 weeks since prior major surgery&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Use of antibiotics for marginal zone lymphoma does not count as a prior therapy&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
&#xD;
          -  No other concurrent anticancer therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Owen A. O'Connor, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vermont Cancer Center at University of Vermont</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05401-3498</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2006</verification_date>
  <study_first_submitted>January 24, 2003</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>June 21, 2013</last_update_submitted>
  <last_update_submitted_qc>June 21, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2013</last_update_posted>
  <keyword>refractory chronic lymphocytic leukemia</keyword>
  <keyword>B-cell chronic lymphocytic leukemia</keyword>
  <keyword>recurrent grade 1 follicular lymphoma</keyword>
  <keyword>recurrent grade 2 follicular lymphoma</keyword>
  <keyword>recurrent grade 3 follicular lymphoma</keyword>
  <keyword>Waldenström macroglobulinemia</keyword>
  <keyword>recurrent marginal zone lymphoma</keyword>
  <keyword>recurrent small lymphocytic lymphoma</keyword>
  <keyword>recurrent mantle cell lymphoma</keyword>
  <keyword>extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue</keyword>
  <keyword>nodal marginal zone B-cell lymphoma</keyword>
  <keyword>splenic marginal zone lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Lymphoproliferative Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

